




Sol-Gel
Advanced Topical Therapy

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “future,” “outlook,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this presentation relate to, among other things, statements regarding the Food and Drug Administration (FDA) approval, the strategic partnership with Galderma, the sale of generic assets to Padagis, progress on our innovative earlier stage programs, including the anticipated timing of the clinical development of SGT-510, SGT-310 and SGT-210, the future markets for various skin diseases, and, our expectations regarding our liquidity and ability to fund operational and capital expenditure requirements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statement, including but not limited to the following: risks relating to the timing of the PDUFA action date for EPSOLAY, the timing of FDA approval, if any, of EPSOLAY; the risk that we will not be successful in marketing additional products and the timing of such marketing; the risk that we will not receive the anticipated benefits of the strategic partnership with Galderma or the agreement with Padagis; the risk that we don't progress on our innovative earlier stage programs, the risk of a delay in the clinical development of SGT-510, SGT-310 and SGT-210, if any; the risk that our estimate of the markets for psoriasis and plaque psoriasis are inaccurate; the fact that we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our ability to complete the development of, and obtain marketing approval for, our product candidates; our ability to obtain and maintain regulatory approvals for our product candidates in our target markets and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; our ability to commercialize and launch our product candidates at all or on a timely basis; our ability to obtain and maintain adequate protection of our intellectual property; our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; acceptance of our product candidates by healthcare professionals and patients; the possibility that we may face third-party claims of intellectual property infringement; the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; delays in the launch of product candidates and generic drugs; intense competition in our industry; potential product liability claims; potential adverse federal, state, and local government regulation in the United States, Europe, or Israel; the impact of pandemics, such as COVID-19 (coronavirus); and loss or retirement of key executives and research scientists. These and other important factors discussed in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 4, 2021, and in our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. Any such forward-looking statements represent management's estimates as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation. This presentation contains trademarks, trade names, and service marks of other companies, which are the property of their respective owners. We do not intend our use or display of other parties' trademarks, trade names, or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

PURSUING LEADERSHIP in DERMATOLOGY

Innovative Pipeline of Topical Skin Medications



ACHIEVING FDA APPROVAL and BUILDING our FUTURE

Investor Highlights



- Completed development of EPSOLAY and TWYNEO on time
- Gained FDA approval for TWYNEO
- EPSOLAY pre-approval inspection is pending



- Generated non-dilutive income totaling \$46 million from agreements with Galderma and royalties from two generic drugs



- Maximized probability of launch success for EPSOLAY and TWYNEO through commercialization agreements with US market leader, Galderma
- Retained the option to regain commercialization rights 5 years following 1st commercial sale



- Secured additional \$21 million by transferring rights in 2 generic drugs and 8 unapproved programs to Padagis
- Retained rights to 4 high-value generic drug candidates



- Defined innovative product pipeline which targets multiple US markets exceeding \$2 billion



- Built a strong balance sheet that currently allows us to finance our activities until the end of 2023

MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO

Strategic Partnership with Market Leader Galderma

EPSOLAY®

TWYNEO®

GALDERMA

EST. 1981

MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO

Galderma Leads the US Acne and Rosacea Markets




GALDERMA

EST. 1981

MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO

Galderma is Committed to Innovation



GALDERMA

EST. 1981

MAXIMIZING COMMERCIALIZATION SUCCESS of EPSOLAY and TWYNEO

Strategic Partnership with Market Leader Galderma

- Up to \$15 million in upfront and product approval payments
- Mid- to high-teen percentage of net sales royalties
- Up to an additional \$9 million in sales milestone payments
- Option to regain commercialization rights 5 years following 1st sale at no cost to Sol-Gel

GALDERMA
EST. 1981

- Cash-flow positive deal as of launch
- Focusing on innovative pipeline

FOCUSING on INNOVATIVE PIPELINE while SECURING NON-DILUTIVE FUNDING

Sale of Generic Assets to Padagis

- 2 generic drugs: acyclovir cream and ivermectin cream
- 8 unapproved generic programs



FOCUSING on INNOVATIVE PIPELINE while SECURING NON-DILUTIVE FUNDING

Sale of Generic Assets to Padagis

- \$21 million in quarterly installments over 24 months
- Proceed with 50/50 gross profit-sharing collaboration on 2 programs encompassing 4 high-value generic drug candidates



- Focusing on innovative pipeline
- Reducing the need to raise dilutive capital

OFFERING COMPREHENSIVE TREATMENT for ACNE PATIENTS

First and only FDA Approved Fixed-Dose Combination of Tretinoin and Benzoyl Peroxide

TWYNEO®

- Acne vulgaris is a multifactorial disease. Even though benzoyl peroxide and tretinoin are widely prescribed separately and have a complimentary mechanism of action, so far, they could not be applied concomitantly because benzoyl peroxide decomposes tretinoin
- TWYNEO contains a fixed-dose combination of tretinoin and benzoyl peroxide, using Sol-Gel's patented technology to prevent tretinoin from being degraded by benzoyl peroxide and slowly releasing each of the active drug ingredients over time to provide a favorable efficacy and safety profile
- Patent protected until 2038 by granted patents and until 2041 by a pending patent application

TREATING SEVERE ACNE PATIENT

Subject 507-003 || 18 Years Old | Female | White | Not Hispanic or Latino*

BASELINE



"Severe"; 29 inflamed lesions
31 non-inflamed lesions; 1 nodule

WEEK 12



"Moderate"; 9 inflamed lesions
5 non-inflamed lesions; No nodules

OFFERING a NEW EFFECTIVE TOPICAL TREATMENT for ROSACEA PATIENTS

First and only Benzoyl Peroxide in Inflammatory Lesions of Rosacea*

EPSOLAY®

- Inflammatory lesions of rosacea resemble acne vulgaris, except that comedones (whiteheads and blackheads) are absent and only inflammatory lesions exist
- EPSOLAY contains encapsulated benzoyl peroxide, using Sol-Gel's patented technology. Benzoyl peroxide is an effective antibacterial drug that is not associated with bacterial resistance and is used to treat acne but not rosacea as it is assumed that rosacea patients cannot tolerate benzoyl peroxide. In Phase III clinical studies, EPSOLAY demonstrated statistically significant higher efficacy than the vehicle and favorable safety and tolerability profile, similar to vehicle
- PDUFA goal date was set for April 26, 2021. Awaiting FDA's pre-approval inspection; delayed due to COVID-19 travel restrictions
- Patent protected until 2040 by granted patents and until 2041 by a pending patent application

* EPSOLAY is investigational drug product. Safety and efficacy have not been established

TREATING SEVERE ROSACEA PATIENT

Subject 116-009 || 41 Years Old | Female | White | Not Hispanic or Latino*



DEVELOPING FIRST ERLOTINIB TOPICAL DRUG

SGT-210 for Palmoplantar Keratoderma and other Skin Conditions

A proof-of-concept clinical study in palmoplantar keratoderma patients indicated a potential modest improvement with a favourable safety profile

12 patent applications for erlotinib in various skin conditions (as of August 16, 2021)

Potential IP protection until 2041



NEXT
STEPS
SGT-210

Initiate clinical development with a higher concentration of erlotinib in H2 22

DEVELOPING NOVEL TAPINAROF CREAM

SGT-310 for Psoriasis and other Skin Conditions

SGT-310 is intended to be an alternative to an investigational tapinarof cream, 1%, for which an NDA was already submitted to the FDA

31 patent applications for tapinarof in various skin conditions (as of August 16, 2021)

Potential IP protection until 2042

NEXT
STEPS
SGT-310

Initiate clinical development in H2 22

DEVELOPING NOVEL ROFLUMILAST TOPICAL DRUG

SGT-510 for Psoriasis and other Skin Conditions

SGT-510 is designed to be potentially more effective than roflumilast cream, 0.3%, for which an NDA was already submitted to the FDA

A patent application was filed

Potential IP protection until 2039



NEXT
STEPS
SGT-510

Initiate clinical development in H2 22

BUILDING a STRONG BALANCE SHEET

Financial Profile

Financials

September 30, 2021

Cash and Investments	\$45.6 million
Shares Outstanding	23,119,068 ordinary shares
Expected Partnership Payments	EPSOLAY approval milestone payment (if approved this year); Quarterly payments by Padagis; Royalties from Galderma
Cash Runway	Based on expected payments from Galderma and Padagis, we anticipate that our cash resources will enable funding of operational and capital expenditure requirements until the end of 2023





Sol-Gel
Advanced Topical Therapy